EyePoint Q3 net product revenue $9.7M (+13% YoY); initiates two Phase 2 trials for EYP-1901; DEXYCU termination

EyePoint, Inc.

2022-Q3 EPS reported -$1.58 revenue$30,871,000

Q3 net product revenue $9.7M (+13% YoY); net loss $18.4M ($0.49 diluted EPS) vs $16.7M loss prior year.
Initiated Phase 2 DAVIO 2 (wet AMD) and Phase 2 PAVIA (NPDR) for EYP-1901; topline data expected Q4 2023.
Final 12-month Phase 1 DAVIO data showed positive safety: 73% reduction in treatment burden, no ocular SAEs.
DEXYCU commercialization agreement terminated effective Dec 31, 2022 due to CMS pass-through denial.
Cash $157.3M; expect to fund operations into H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EyePoint, Inc. reported third quarter ended September 30, 2022 results: revenue $10.0 million, net income $18.4 million, EPS ($.49) per share.

Period: third quarter ended September 30, 2022
Revenue: $10.0 million
Net income: $18.4 million
EPS: ($.49) per share
Result: reported results

Exact text from the filing

For the third quarter ended September 30, 2022, total net revenue was $10.0 million compared to $9.1 million for the quarter ended September 30, 2021. Net product revenue for the third quarter was $9.7 million, compared to net product revenues for the third quarter ended September 30, 2021 of $8.6 million. Net revenue from royalties and collaborations for the third quarter ended September 30, 2022 totaled $0.3 million compared to $0.5 million in the corresponding period in 2021. Operating expenses for the third quarter ended September 30, 2022 totaled $28.4 million versus $24.4 million in the prior year period, primarily driven by investment in personnel across the organization, including non-cash stock compensation, and ongoing clinical trial and development costs for EYP-1901. Non-operating expense, net, totaled $0.02 million and net loss was $18.4 million, or ($.49) per share, compared to a net loss of $16.7 million, or ($0.58) per share, for the prior year period.

View on SEC.gov

Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-020968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.